Tivic Secures Non-Dilutive NIAID Funding for Entolimod GI-ARS Drug Development
summarizeSummary
Tivic Health Systems has secured a significant agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for the non-clinical evaluation of its drug candidate, Entolimod, targeting gastrointestinal acute radiation syndrome (GI-ARS). Crucially, NIAID will fund and conduct all preclinical studies, including initial mouse models, at no cost to Tivic. This development is highly material for the micro-cap company, especially following recent negative news regarding a Nasdaq non-compliance notification and a substantial increase in net loss for 2025. The non-dilutive funding from a reputable government agency significantly de-risks the development pathway for a key pipeline asset, reduces capital requirements, and could accelerate regulatory approval under the FDA's Animal Rule. Traders will closely monitor the progress and results of these preclinical studies, as well as any further updates on the company's financial health and Nasdaq compliance.
At the time of this announcement, TIVC was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.72 to $13.23. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Access Newswire.